Menu
Oslo, Norway, 16 March 2026 – Reference is made to the stock exchange announcement made by Thor Medical ASA (the "Company") on 13 March 2026 regarding the registration of the share capital increase pertaining to the issuance of new shares in connection with the exercise of options under the share option program in the Company.
Today, following registration of the share capital increase, 4,041,666 shares have been redelivered to Scatec Innovation AS pursuant to the Share Lending Agreement entered into in connection with the cash-less exercise for the options, as noted in the stock exchange announcement on 27 February 2026.
Reference is further made to the stock exchange announcements made by the Company on 27 February and 2 March 2026 regarding respectively the exercise of share options and the completed primary insider purchases after the option exercise. The Company's CFO and COO, Brede Ellingsæter, has transferred all shares acquired under the share option program to B Good Industries AS, where Brede Ellingsæter is the chair of the board, a close associate of a primary insider of the Company.
Notification of the redelivery and transfer of shares in accordance with the Market Abuse Regulation article 19 is attached to this announcement.
For further information please contact:
Mathias Nilsen Reierth
Head of Communications and Corporate Affairs
Tel: +47 988 05 724
mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Securities Trading Act.
